Development of pemphigus vegetans and exacerbation of pemphigus foliaceus after secukinumab loading in a patient with complicated generalized pustular psoriasis and pyoderma gangrenosum

• Published in: Journal of dermatology Vol. 50; no. 2; pp. 245 - 249
• Main Authors: Minai, Lisa, Takeichi, Takuya, Ogawa, Youichi, Honobe‐Tabuchi, Akiko, Okamoto, Takashi, Mitsui, Hiroshi, Shimada, Shinji, Akiyama, Masashi, Kawamura, Tatsuyoshi
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.02.2023
• Subjects: Atopic dermatitis; Autoimmune diseases; Dermatitis, Atopic - complications; generalized pustular psoriasis; Humans; Interleukin 13; Monoclonal antibodies; Pemphigus; Pemphigus - complications; Pemphigus - drug therapy; pemphigus foliaceus; pemphigus vegetans; Psoriasis; Psoriasis - complications; Psoriasis - drug therapy; Pyoderma; Pyoderma gangrenosum; Pyoderma Gangrenosum - chemically induced; Pyoderma Gangrenosum - complications; Pyoderma Gangrenosum - drug therapy; secukinumab; Skin diseases; Skin Diseases, Vesiculobullous - complications; pemphigus foliaceus; generalized pustular psoriasis; pyoderma gangrenosum; secukinumab; pemphigus vegetans
• ISSN: 0385-2407; 1346-8138; 1346-8138
• DOI: 10.1111/1346-8138.16563

In dermatology, biologics that block signaling pathways of TNF‐α, IL‐4/IL13, IL‐17s, and IL‐23 are widely used for the treatment of several inflammatory skin diseases, such as atopic dermatitis and psoriasis. They have shown excellent efficacy with an acceptable safety profile. However, these biologics targeting pathogenic cytokines and their receptors could modulate immunological balance, leading to the development of other inflammatory or autoimmune skin diseases in some cases. In this study, we present a patient who suffered pemphigus vegetans and showed an exacerbation of pemphigus foliaceus after secukinumab loading for the treatment of complicated generalized pustular psoriasis and pyoderma gangrenosum.